Modern Pediatrics. Ukraine. (2024). 5(141): 66-72. doi: 10.15574/SP.2024.5(141).6672
Alekseieva Yu. I., Synoverska O. B., Dutchak G. M., Urbas O. V., Ivanyshyn L. Ya.
Ivano-Frankivsk National Medical University, Ukraine

For citation: Alekseieva YuI, Synoverska OB, Dutchak GM, Urbas OV, Ivanyshyn LYa. (2024). Mechanisms of development, diagnosis and conservative therapy of Crohn's disease in pediatric practice. Modern Pediatrics. Ukraine. 5(141): 66-72. doi: 10.15574/SP.2024.5(141).6672.
Article received: Apr 01, 2024. Accepted for publication: Sep 09, 2024.

In recent years, the incidence of Crohn's disease has significantly increased among both adult and pediatric populations, currently standing at 58 per 100,000 individuals.
This study aims to investigate the primary etiopathogenetic features, diagnostic methods, and conservative treatment options for this condition in children, based on a comprehensive literature review.
It highlights the fundamental differences, including higher disease activity scores, more complicated course of the disease, with the involvement of other organs and systems in the pathological process, difficulty of diagnosis and  resistance to treatment, adverse impact on the child's growth and development, presence of protein and energy deficiency manifestations, impaired  of psychosocial functions and adaptation capabilities in both physical and social spheres. Among the main etiological and pathogenetic factors of the disease, the genomic theory, infectious theory, intestinal microbiome influence, imbalance of cytokine regulation with an increase in the content of pro-inflammatory cytokines and environmental factors are considered. On the basis of the conducted analysis, it was established that at the current stage, a significant spread of the inflammatory process is determined, which is diagnosed for one meter or more of digestive tract, with the formation of crypt-abscesses and the development of deep ulcers. The main clinical syndromes and complications that characterize the course of this disease and its features in children are described. Modern principles of diagnosis and conservative treatment of pathology are considered, in which the use of mesalazines and antibiotics is highlighted. It is emphasized the need to use enteral therapy and, in the absence of an effect from treatment, the need for a timely transition to the use of immunomodulators, biologics in the treatment regimen.
The authors declare that there is no conflict of interest concerning the publication of this article.
Keywords: children, Crohn's disease, etiology, pathogenesis, clinical manifestation, treatment
REFERENCES

1. Agnarsson U, Björnsson S, Jóhansson JH, Sigurdsson L. (2013). Inflammatory bowel disease in Icelandic children 1951-2010. Population-based study involving one nation over six decades. Scand J Gastroenterol. 357: 1399-404. https://doi.org/10.3109/00365521.2013.845799

2. Alfadhli AA, McDonald JW, Feagan BG. (2005). Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 01: CD003459. https://doi.org/10.1002/14651858.CD003459.pub2

3. Amre DK, Lu SE, Costea F, Seidman EG.(2006). Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 357: 645-52. https://doi.org/10.1111/j.1572-0241.2006.00468.x

4. Belska OA. (2015). Problemni pytannia diahnostyky ta likyvannia khvoroby Krona u ditej. Dytiachyi likar. 2(39): 16-22.

5. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. (2011). Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 17(01): 423-439. https://doi.org/10.1002/ibd.21349

6. Borrelli O, Cordischi L, Cirulli M et al. (2006). Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 4(6): 744-753. https://doi.org/10.1016/j.cgh.2006.03.010

7. Cameron FL, Wilson ML, Basheer N et al. (2015). Anti-TNF therapy for paediatric IBD: the Scottish national experience. Arch Dis Child. 100(4): 399-405. https://doi.org/10.1136/archdischild-2013-305812

8. Castellaneta SP, Afzal NA, Greenberg M et al. (2004). Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 357: 257-261. https://doi.org/10.1097/00005176-200409000-00006

9. Castro M, Papadatou B, Baldassare M et al. (2008). Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003). Inflamm Bowel Dis. 357: 1246-52. https://doi.org/10.1002/ibd.20470

10. Chiorean L, Schreiber-Dietrich D, Braden B et al. (2015). Ultrasonographic imaging of inflammatory bowel disease in pediatric patients. World J Gastroenterol. 7; 21(17): 5231-5241. https://doi.org/10.3748/wjg.v21.i17.5231

11. Colombel JF, Rutgeerts P, Reinisch W et al. (2008). SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease nave to immunomodulators and biologic therapy. Gut. 57; Suppl II: A1. https://doi.org/10.1002/ibd.20829

12. Conte MP, Schippa S, Zamboni I et al. (2006). Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 357: 1760-1767. https://doi.org/10.1136/gut.2005.078824

13. De Boer MD, Denson LA. (2013). Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains. J Pediatr. 163(01): 17-22. https://doi.org/10.1016/j.jpeds.2013.02.010

14. Debruyn JC, Soon IS, Hubbard J, Wrobel I, Panaccione R, Kaplan GG.(2013). Nationwide temporal trends in incidence of hospitalization and surgical intestinal resection in pediatric inflammatory bowel diseases in the United States from 1997 to 2009. Inflamm Bowel Dis. 19(11): 2423-2432. https://doi.org/10.1097/MIB.0b013e3182a56148

15. De Zoeten EF, Pasternak BA, Mattei P, Kramer RE, Kader HA. (2013). Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr. 357: 401-412. https://doi.org/10.1097/MPG.0b013e3182a025ee

16. Didnass A, Van Assche G, Lindsay J et al. (2010). for the European Crohn's Colitis Organisation – ECCO. The second European evidence based consensus on the diagnostic and management of Crohn's disease: current management. JCC. 4: 28-62. https://doi.org/10.1016/j.crohns.2009.12.002

17. Duerr RH, Taylor KD, Brant SR et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 357: 1461-1463. https://doi.org/10.1126/science.1135245

18. Gevers D, Kugathasan S, Denson LA et al. (2014). The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 357: 382-392. https://doi.org/10.1016/j.chom.2014.02.005

19. Gupta N, Bostrom AG, Kidchner DS. (2007). Gebder Differences in Presentation and course of Disease in Pediatric Patients With Crohn Disease. Pediatrics. 120; 6: 1418-1425. https://doi.org/10.1542/peds.2007-0905

20. Henderson P, Anderson NH, Wilson DC. (2014). The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 109(5): 637-645. https://doi.org/10.1038/ajg.2013.131

21. Jose FA, Garnett EA, Vittinghoff E et al. (2009). Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 15(1): 63-68. https://doi.org/10.1002/ibd.20604

22. Khan KJ, Ullman TA, Ford AC et al. (2011). Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 106: 661-673. https://doi.org/10.1038/ajg.2011.72

23. Krjuchko TO, Nesina IM, Poda OA, Kolenko IO. (2016). Algorithm for differential diagnosis of intestinal diseases in children. Dytiachyi likar. 48: 21-24.

24. Lahad A, Weiss B. (2015). Current therapy of pediatric Crohn's disease. World J Gastrointest Pathophysiol. 357: 33-42. https://doi.org/10.4291/wjgp.v6.i2.33

25. Levine A, Koletzko S, Turner D et al. (2014). ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 58(6): 795-806. https://doi.org/10.1097/MPG.0000000000000239

26. Liu JZ, van Sommeren S, Huang H et al. (2015). International Multiple Sclerosis Genetics Consortium International IBD Genetics Consortium. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 357: 979-986. https://doi.org/10.1038/ng.3359

27. Loly C, Belaiche J, Louis E. (2008). Predictors of severe Crohn's disease. Scand J Gastroenterol. 43: 948-954. https://doi.org/10.1080/00365520801957149

28. Malmborg P, Grahnquist L, Lindholm J, Montgomery S, Hildebrand H.(2013). Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007. J Pediatr Gastroenterol Nutr. 357: 29-34. https://doi.org/10.1097/MPG.0b013e31828f21b4

29. Matsuoka K, Kanai T. (2015). The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 357: 47-55. https://doi.org/10.1007/s00281-014-0454-4

30. Menachem Y, Weizman Z, Locker C, Odes S. (1998). Clinical characteristics of Crohn's disease in children and adults Harefuah. 1; 134(3): 173-275, 247.

31. Miele E, Shamir R, Aloi M et al. (2018, Apr). Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 66(4): 687-708. https://doi.org/10.1097/MPG.0000000000001896

32. Naramore SK, Bennett WE Jr, Jiang G et al. (2019). Serologic, but Not Genetic, Markers Are Associated With Impaired Anthropometrics at Diagnosis of Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr. 69(5): e129-e134. https://doi.org/10.1097/MPG.0000000000002462

33. Peyrin-Biroulet L, Sandborn W, Sands BE et al. (2015). Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 357: 1324-1338. https://doi.org/10.1038/ajg.2015.233

34. Pigneur B, Seksik P, Viola S et al. (2010). Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 357: 953-961. https://doi.org/10.1002/ibd.21152

35. Poda OA. (2021). Khvoroba Krona u ditei: aktualni aspekty diahnostyky ta likuvannia zghidno z suchasnymy mizhnarodnymy rekomendatsiiamy Zdorov'e Rebenka. 16(1): 75-83. https://doi.org/10.22141/2224-0551.16.1.2021.226461

36. Ruemmele FM, Veres G, Kolho KL et al. (2014). Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 8(10): 1179-11207. doi: 10.1016/j. crohns.2014.04.005.

37. Rufo PA, Denson LA, Sylvester FA et al. (2012). Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr. 357: 93-108. https://doi.org/10.1097/MPG.0b013e31825959b8

38. Shadrin OG, Misnyk VP, Marushko TL, Mostovenko RV. (2023). Crohn's disease in young children. Difficult path to diagnosis. Modern Pediatrics. Ukraine. 3(131): 111-120. https://doi.org/10.15574/SP.2023.131.111

39. Siddiki HA, Fidler JL, Fletcher JG et al. (2009). Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol. 193(01): 113-121. https://doi.org/10.2214/AJR.08.2027

40. Skrypnyk IM. (2019). Inflammatory bowel disease: 14th Congress of the European Organization for the Study of Crohn's Disease and Colitis (ECCO). Modern Gastroenterology. 107: 107-108. https://doi.org/10.30978/MG-2019-3-107

41. Tillack C, Seiderer J, Brand S et al. (2008). Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn's disease. Inflamm Bowel Dis. 14(09): 1219-1228. https://doi.org/10.1002/ibd.20466

42. Uhlig HH, Schwerd T, Koletzko S et al. (2014). COLORS in IBD Study Group and NEOPICS. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 357: 990-1007.e3. https://doi.org/10.1053/j.gastro.2014.07.023

43. Von Allmen D. (2018). Pediatric Crohn's Disease. Clin Colon Rectal Surg. 31(2): 80-88. Published online 2018 Feb 25. https://doi.org/10.1055/s-0037-1609022

44. Weiss B, Turner D, Griffiths A et al. (2019). Simple Endoscopic Score of Crohn Disease and Magnetic Resonance Enterography in Children: Report From ImageKids Study. J Pediatr Gastroenterol Nutr. 69(4): 461-465. https://doi.org/10.1097/MPG.0000000000002404

45. Willot S, Noble A, Deslandres C. (2011). Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis. 17(12): 2521-2526. https://doi.org/10.1002/ibd.21653